Physician profile
Scott Pfeffer
NPI 1982607842
$8,317.92
in general payments reported to CMS, 2019-2025
35 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $976 · 2021: $1,584 · 2022: $1,570 · 2023: $1,405 · 2024: $1,334 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $936.84 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $758.83 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $722.17 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $710.60 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $653.94 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $490.41 | 2020-2024 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $424.05 | 2019-2024 | |
| Boston Scientific Corporation | $412.27 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astellas Pharma US INC | $398.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $388.32 | 2020-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.54 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $306.85 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.48 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $222.10 | 2021-2024 | Nexletol |
| Novo Nordisk INC | $195.65 | 2021-2025 | Ozempic, Rybelsus |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $139.94 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $120.24 | 2020-2022 | |
| Medtronic, INC. | $118.96 | 2022-2024 | Attain Command + Surevalve, Linq II, Mycarelink |
| Bayer Healthcare Pharmaceuticals INC. | $116.87 | 2021-2025 | |
| Althera Pharmaceuticals LLC | $84.97 | 2021 | |
| Philips North America LLC | $51.92 | 2021-2025 | Event |
| Scpharmaceuticals INC. | $48.70 | 2025 | |
| Akcea Therapeutics, INC. | $39.97 | 2020-2021 | |
| Inspire Medical Systems, INC. | $38.03 | 2023-2024 | Inspire |
| Edwards Lifesciences Corporation | $37.02 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kiniksa Pharmaceuticals, Ltd. | $35.97 | 2023 | Arcalyst |
| Abbott Laboratories | $34.93 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Regeneron Healthcare Solutions, INC. | $32.94 | 2019 | |
| Heartflow, INC. | $29.62 | 2025 | |
| Irhythm Technologies, INC. | $24.80 | 2022 | |
| Kestra Medical Technology Services, INC. | $23.21 | 2024 | Assure Wcd |
| Siemens Medical Solutions USA, INC. | $22.32 | 2023 | Luminos Agile Max |
| Impulse Dynamics (USA) INC. | $20.30 | 2024 | Optimizer |
| Biogen, INC. | $18.02 | 2024 | Skyclarys |
| Atricure, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pfeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.